Metadata record for the manuscript: OMO-1 reduces tumor progression and enhances cisplatin efficacy in a 4T1-based non c-MET addicted intraductal mouse model for triple-negative breast cancer

Summary

This
metadata record provides details of the data supporting the claims of the
related manuscript: “OMO-1 reduces tumor progression and
enhances cisplatin efficacy in a 4T1-based non c-MET addicted intraductal mouse
model for triple-negative breast cancer ”.

The
related study investigated the therapeutic efficacy of OMO-1, a potent and
selective c-MET inhibitor, in an immunocompetent intraductal mouse model for
triple-negative breast cancer (TNBC).

Type of data:
Histology and immunohisto/cytochemistry, spreadsheets, western blot analysis

Subject of data:
4T1 cell culture, BALB/c mice

Sample size:
4 mice

Data
access

The histology
and immunohisto/cytochemistry, spreadsheets and western blot analysis data are
not publicly available for the following reason: a
patent application on OMO-1 in non c-MET addicted tumours is still pending. However,
the data can be made available upon reasonable request to the corresponding
author. A comprehensive list of the datafiles underlying each of the
figures and supplementary figures in the related manuscript is shared together
with this metadata record in the file ‘Steenbrugge_et_al_2021_data_underlying_figures.xlsx’.

Corresponding author(s) for this study

Jonas
Steenbrugge, Laboratory of Biochemistry, Department of Pharmacology, Toxicology
and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
e-mail: [e-mail].

Study approval

The
Ethical Committee (EC) of the Faculty of Veterinary Medicine, Ghent University
(EC 2018-37 and amendment EC 2018-65).